Peptide Library

The first GLP-1 weight-loss drug you can just swallow, approved by the FDA in 2026.

A weight-loss drug that pairs the appetite hormone with the blood-sugar-raising one — and shows a striking effect on the liver.

A long-acting copy of the fullness hormone amylin — a second appetite mechanism that is not another GLP-1.

Eli Lilly's copy of the fullness hormone amylin, showing a remarkable 20% weight loss from a mechanism that skips GLP-1 entirely.

The 'wolverine stack' — two repair mechanisms in one vial, a decade of folklore and zero controlled trials.

The anti-inflammatory tail of a pigmentation hormone, stripped of the side effects, with strong lab logic but almost no human trials.

The actin-binding engine of TB-500 sold as a substitute at a sixth of the cost, where the engine works but the missing parts matter.

The most advanced attempt yet to keep the gut lining tight — a promising idea that failed its final test.

A gut-repair pairing: BPC-157 rebuilds the tissue while KPV quiets the inflammation feeding the damage.

A fragment of erythropoietin designed to protect injured tissue without making red blood cells — elegant in animals, disappointing in people.

The supposed fat-burning end of growth hormone, isolated and sold freely, even though the upgraded version already failed in human trials.

It reliably releases growth hormone, but so does ipamorelin, without the cortisol, prolactin, and hunger that come along with this one.

The best-studied fat-burning fragment was tested honestly in full clinical trials and lost.

Engineered to escape the body's natural brakes on a growth signal, it builds muscle while raising one of the cleanest cancer-risk flags in epidemiology.

A growth-hormone stack with one FDA-approved half and a selective signal from the other.

The early growth-hormone stack — the receptor logic is textbook, but one of its two halves is the dated version.

A potent GH-releasing peptide — strong hit, but it desensitizes and is less 'clean.'

The oral GH enhancer — take a pill, sustain elevated GH and IGF-1 for a full day.

A rodent memory molecule its developer's own company passed on, with a cancer-relevant mechanism that makes the risk real.

A seven-amino-acid fragment studied as an antidepressant — in mice, by one lab, never in a human.

A supposedly improved version of Semax — but the molecule has never been tested, and its record is completely empty.

A Russian pineal-gland peptide sold as a lifespan extender on the strength of one lab's single unreplicated human study.

The first peptide ever found hiding inside mitochondrial DNA, with strong protective biology and zero human trials.

A calf-thymus extract with decades of clinical reporting — and not one study you can look up in a registry.

The peptide for clearing out 'zombie' cells — deep-research territory, huge longevity buzz.

The cosmetic-first cousin of KLOW — three peptides aimed at skin and recovery, weighted toward GHK-Cu.

A real FDA-approved drug for a rare sun-intolerance disease, sold at the same time as a gray-market tanning shot that is not the approved product.

Marketed as 'topical Botox,' it is an eight-amino-acid skincare peptide fighting an uphill battle to reach the muscle through your skin.

An accidental sex peptide: the tanning-drug team kept noticing everyone got erections.

The master switch for the entire reproductive system — a clean signal, still in phase 2.

A long-acting prostate-cancer drug that some communities reinvented as a single-shot hormone restart, resting on a thin anecdote.

The long-acting erection pill that also treats enlarged prostate and a form of high blood pressure in the lungs.

A lab molecule that switches on your cells' endurance-exercise program in mice and reached the market years before any human trial.

An incretin-class peptide being tested not for weight loss but for addiction — a question the field is watching closely.